SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is facing high volatility as investors speculate on the timing of the 80th clinical event, with the community actively debating whether the current price pullback is a healthy consolidation driven by warrant exercises and profit-taking or a sign of deeper fundamental issues. Long-term bulls remain focused on the upcoming REGAL Phase 3 data, while vocal dissenters continue to challenge the company's clinical history and transparency.

NIO, Inc. operates as a holding company, which engages in the design, development, manufacture, and sale of smart electric vehicles. It offers its products under the brands NIO, ONVO, and FIREFLY. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Shanghai, China.

NIO Inc - ADR

NIO Inc

NIO is trending as the market reacts to strong quarterly financial results, including an earnings beat and bullish delivery guidance, which have fueled ongoing community debate over potential stock manipulation. Investors remain sharply divided between those viewing the current share price as a deep-value accumulation opportunity and those frustrated by persistent price volatility despite the company's improving fundamentals.

Applied Digital Corporation

Applied Digital is surging after announcing a significant 15-year hyperscaler lease for its fourth AI campus, fueling community excitement over a growing multibillion-dollar backlog and rising analyst price targets. Shareholders are actively debating the potential for an imminent short squeeze and expressing high conviction in the firm's long-term infrastructure strategy.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum is trending following a proposed $100 million equity-backed investment from the U.S. government, sparking intense debate between bulls citing national strategic importance and bears pointing to fundamental concerns regarding low revenue and share dilution. The community remains deeply divided, with active discussion focusing on whether this government endorsement signals a long-term sector mandate or merely a volatile momentum play for speculative traders.

Arm Holdings Plc engages in the licensing, marketing, research, and development of microprocessors, systems IP, graphics processing units, physical IP and associated systems IP, software, and tools. It operates through the following geographical segments: United Kingdom, United States, and Other Countries. The company was founded on November 12, 1990 and is headquartered in Cambridge, the United Kingdom.

Arm Holdings plc. - ADR

Arm Holdings Plc.

Arm Holdings is experiencing extreme volatility as investors digest a combination of robust growth in its AGI CPU pipeline and concerns over supply constraints that capped near-term expectations. The community remains deeply divided, with many traders debating whether current price swings represent a healthy consolidation for a long-term AI infrastructure play or the bursting of a valuation bubble.

Intuit, Inc. engages in the provision of business and financial management solutions. It operates through the following segments: Small Business and Self-Employed, Consumer, Credit Karma, and ProTax. The Small Business and Self-Employed segment offers QuickBooks financial and business management online services and desktop software, payroll solutions, payment processing solutions, and financing for small businesses. The Consumer segment includes do-it-yourself and assisted TurboTax income tax preparation products and services. The Credit Karma segment serves consumers with a personal finance platform that provides personalized recommendations of credit cards, home, auto and personal loans, and insurance products, and online savings and checking accounts. The ProTax segment refers to the professional accountants in the U.S. and Canada, who are essential to both small business success and tax preparation and filing. The company was founded by Scott D. Cook and Thomas A. Proulx in March 1983 and is headquartered in Mountain View, CA.

Intuit Inc

Intuit shares are facing intense selling pressure following a double-beat earnings report, as investors focus on a 17% workforce reduction and concerns regarding competitive pricing headwinds. The community is sharply divided between those viewing the decline as a major buying opportunity due to strong fundamentals and share buybacks, and those fearing structural disruption from AI alternatives impacting the company's core tax software business.

Infleqtion, Inc. engages in delivering neutral atom solutions for quantum computing, networking, sensing, and security. Its products are categorized into computing, sensing, and cores. The company was founded on February 7, 2007, and is headquartered in Louisville, CO.

Infleqtion Inc. - Ordinary Shares - Class A

Infleqtion Inc.

Infleqtion is seeing massive momentum and extreme trading volume following news that the company secured a significant letter of intent for government funding to accelerate its neutral-atom quantum technology. The community is actively debating the company's valuation relative to its peers and the long-term strategic validation provided by federal equity stakes.

Enphase Energy, Inc. is a global energy technology company, which engages in the business of designing, developing, manufacturing, and selling home energy solutions that manage energy generation, energy storage, control, and communications on one intelligent platform. It operates through the following geographical segments: the United States, the Netherlands, and Others. The company was founded by Raghuveer R. Belur and Martin Fornage in March 2006 and is headquartered in Fremont, CA.

Enphase Energy Inc

Enphase Energy is generating intense debate as it pivots toward AI data center infrastructure through its new solid-state transformer technology, even as the stock faces downward pressure from ongoing challenges in the residential solar sector. While retail investors remain divided between viewing the move as a major long-term re-rating catalyst and concerns over persistent fundamental headwinds, high short interest has turned the ticker into a volatile battleground for active traders.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

Rigetti Computing (RGTI) is trending following a massive industry-wide rally triggered by reports of a multi-billion dollar U.S. government investment initiative in quantum technology. The community is sharply divided, with bulls pointing to the long-term strategic validation of the sector, while bears criticize the speculative valuations and high cash burn of these companies.

Walmart, Inc. engages in the retail and wholesale business. The company offers an assortment of merchandise and services at everyday low prices. It operates through the following business segments: Walmart U.S., Walmart International, and Sam's Club. The Walmart U.S. segment operates as a mass merchandiser of consumer products, operating under the Walmart and Walmart Neighborhood Market brands, including walmart.com. The Walmart International segment includes operations of wholly-owned subsidiaries in Canada, Chile, China, and Africa, and majority-owned subsidiaries in India, as well as Mexico and Central America. The Sam's Club segment manages membership-only warehouse clubs and operates samsclub.com. The company was founded by Samuel Moore Walton and James Lawrence Walton on July 2, 1962 and is headquartered in Bentonville, AR.

Walmart Inc

Walmart is currently trading near historical highs as investors lean into the stock as a defensive "safe haven" amidst broader market volatility and inflationary pressures. While the company faces intense scrutiny over its high valuation multiples, the community remains actively divided between those betting on continued growth through retail dominance and those expecting a significant pullback due to stretched fundamentals.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Insider Buying: Alzamend Neuro (NASDAQ:ALZN) Director Buys 108,388 Shares of Stock

Alzamend Neuro, Inc. (NASDAQ:ALZN - Get Free Report) Director Milton Ault III bought 108,388 shares of the stock in a transaction dated Tuesday, April 14th. The shares were purchased at an average price of $1.00 per share, for a total transaction of $108,388.00. Following the purchase, the director...

Alzamend Neuro Reports Encouraging Pharmacodynamic Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study in a Trial Conducted at Massachusetts General Hospital

Alzamend Neuro Reports Encouraging Pharmacodynamic Data from Phase II Clinical Trial of AL001 'Lithium in Brain' Study in a Trial Conducted at Massachusetts General Hospital Alzamend Neuro Reports...

Alzamend Neuro Reports Positive Topline Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study; AL001 Achieves Bioequivalence and Demonstrates Superior Brain Delivery Across All Measured Brain Regions

Alzamend Neuro Reports Positive Topline Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study; AL001 Achieves Bioequivalence and Demonstrates Superior Brain Delivery Across All Measured Brain Regions Alzamend Neuro Reports Positive Topline Data from Phase II Clinical Trial of AL001...

Alzamend Neuro Initiates Phase II Clinical Trial of AL001 "Lithium in Brain" Study in Patients with Bipolar Disorder in Collaboration with Massachusetts General Hospital

Alzamend Neuro Initiates Phase II Clinical Trial of AL001 'Lithium in Brain' Study in Patients with Bipolar Disorder in Collaboration with Massachusetts General Hospital Alzamend Neuro Initiates...

Is Allogene Therapeutics (ALLO) Stock Outpacing Its Medical Peers This Year?

Here is how Allogene Therapeutics (ALLO) and Alzamend Neuro, Inc. (ALZN) have performed compared to their sector so far this year.

Is AIM ImmunoTech (AIM) Stock Outpacing Its Medical Peers This Year?

Here is how AIM ImmunoTech Inc. (AIM) and Alzamend Neuro, Inc. (ALZN) have performed compared to their sector so far this year.

EMBC Q4 Preview: Product Momentum and Strategy Gains to Support Growth?

Embecta's Q4 earnings loom as product momentum, global trends and recent strategic gains set the stage for potential top-line support.

Alzamend Neuro Announces Completion of Clinical Portion of Phase II Clinical Trial of AL001 "Lithium in Brain" Study Conducted at Massachusetts General Hospital

Alzamend Neuro Announces Completion of Clinical Portion of Phase II Clinical Trial of AL001 'Lithium in Brain' Study Conducted at Massachusetts General Hospital Alzamend Neuro Announces Completion of...

EXCLUSIVE: Alzamend Wraps Clinical Phase Of AL001 Study In Healthy Participants

Alzamend Neuro completed its first Phase 2 trial for AL001, a novel lithium therapy aiming for better brain delivery and safety, reducing the need for drug monitoring.read more...

Shares of Alzamend Neuro, Inc. (ALZN) soared 82% on Thursday afternoon after the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.alzamend.com/news-events/press-releases/detail/93/alzamend-neuro-announces-dosing-of-first-patient-in-its">announced</a> the dosing of the first patient in its first Phase II clinical study of AL001 in healthy human subjects.AL001 is a novel lithium-delivery system that has the potential to provide the benefits of marketed lithium salts while mitigating currently experienced toxicities associated with lithium.The system is designed to favorably distribute lithium in the brain, resulting in lower exposure of other body organs and an improved safety profile compared to currently marketed lithium salts.The study in healthy human subjects is expected to help the company determine the best path forward in Alzheimer’s disease, bipolar disorder, major depressive disorder, and post-traumatic stress disorder patients by demonstrating AL001’s targeted effectiveness and reduced systemic side effects, the company said.Lithium is known for its efficacy as a first-line therapy for manic episodes and maintenance in bipolar disorder.However, current lithium salts require regular lithium therapeutic drug monitoring of plasma lithium levels and blood chemistry by a clinician to mitigate adverse events that could affect the kidneys and thyroid.Alzamend said that AL001 would potentially eliminate the need for lithium therapeutic drug monitoring. The company’s previous studies in mice have shown that AL001 ensures better brain absorption while maintaining lower levels of lithium in the blood, it addedAlzamend CEO Stephan Jackman said that the company is expected to announce data from the new study before the end of the year.“This advancement stands to potentially enhance the lives of over 43 million Americans suffering from Alzheimer’s, BD, MDD, and PTSD,” he added.On Stocktwits, retail sentiment around Alzamend jumped from ‘neutral’ to ‘extremely bullish’ over the past 24 hours while message volume soared from ‘extremely low’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:630/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_29_at_1_18_03_PM_png_9982df14f5.webp" alt="ALZN's Sentiment Meter and Message Volume as of 1:18 p.m. ET on May 29, 2025 | Source: Stocktwits" width="630" height="63"><figcaption>ALZN's Sentiment Meter and Message Volume as of 1:18 p.m. ET on May 29, 2025 | Source: Stocktwits</figcaption></figure> <a href="https://stocktwits.com/symbol/ALZN">ALZN stock</a> is down by about 44% this year and by about 88% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/uber-stock-falls-after-tesla-s-june-12-robotaxi-launch-report/ch0AH7SRbtU">Uber Stock Falls After Tesla’s June 12 Robotaxi Launch Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Alzamend Neuro Stock Rockets On Dosing Of First Human Patient With Lithium-Delivery System AL001 In Phase II Study: Retail’s Thrilled

AL001 has the potential to provide the benefits of marketed lithium salts while mitigating currently experienced toxicities associated with lithium.

Equity

Alzamend Neuro, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which is in Phase II clinical trial, and delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bipolar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders, and AL002, which completed preclinical stage, and uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. The company was founded on February 26, 2016 by Milton C. Ault, III and is headquartered in Atlanta, GA.

ALZN
Alzamend Neuro Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Compact View

Latest ALZN News

ALZNAlzamend Neuro Inc